vs
enCore Energy Corp.（EU）与Lakeside Holding Ltd（LSH）财务数据对比。点击上方公司名可切换其他公司
enCore Energy Corp.的季度营收约是Lakeside Holding Ltd的1.8倍（$12.4M vs $7.0M），Lakeside Holding Ltd净利率更高（-22.6% vs -173.9%，领先151.3%）
德文能源是一家美国 hydrocarbon 勘探企业，公司注册于特拉华州，运营总部位于俄克拉荷马州俄克拉荷马城的德文能源中心，业务区块主要集中在特拉华盆地、伊格尔福特区块以及落基山脉区域，是美国本土重要的能源勘探开发企业。
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
EU vs LSH — 直观对比
营收规模更大
EU
是对方的1.8倍
$7.0M
净利率更高
LSH
高出151.3%
-173.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.4M | $7.0M |
| 净利润 | $-21.5M | $-1.6M |
| 毛利率 | 37.9% | 27.2% |
| 营业利润率 | -135.9% | -21.3% |
| 净利率 | -173.9% | -22.6% |
| 营收同比 | — | 95.0% |
| 净利润同比 | — | 18.7% |
| 每股收益（稀释后） | $-0.11 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EULSH
| Q4 25 | $12.4M | $7.0M | ||
| Q3 25 | $8.9M | $6.1M | ||
| Q2 25 | $3.7M | $6.3M | ||
| Q1 25 | $18.2M | $3.8M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.1M |
净利润EULSH
| Q4 25 | $-21.5M | $-1.6M | ||
| Q3 25 | $-4.8M | $-1.4M | ||
| Q2 25 | $-6.3M | $-893.1K | ||
| Q1 25 | $-24.2M | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | — | $-1.3M |
毛利率EULSH
| Q4 25 | 37.9% | 27.2% | ||
| Q3 25 | 43.8% | 18.2% | ||
| Q2 25 | 30.8% | 26.7% | ||
| Q1 25 | -0.1% | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% |
营业利润率EULSH
| Q4 25 | -135.9% | -21.3% | ||
| Q3 25 | -158.2% | -20.8% | ||
| Q2 25 | -526.1% | -8.9% | ||
| Q1 25 | -85.7% | -28.2% | ||
| Q4 24 | — | -55.6% | ||
| Q3 24 | — | -32.5% |
净利率EULSH
| Q4 25 | -173.9% | -22.6% | ||
| Q3 25 | -53.7% | -22.2% | ||
| Q2 25 | -172.7% | -14.2% | ||
| Q1 25 | -132.9% | -28.2% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | — | -32.7% |
每股收益（稀释后）EULSH
| Q4 25 | $-0.11 | $-0.08 | ||
| Q3 25 | $-0.03 | $-0.09 | ||
| Q2 25 | $-0.03 | $-0.11 | ||
| Q1 25 | $-0.13 | $-0.14 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | — | $-0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $52.4M | $1.6M |
| 总债务越低越好 | $110.0M | $2.4M |
| 股东权益账面价值 | $229.2M | $12.2M |
| 总资产 | $430.4M | $24.3M |
| 负债/权益比越低杠杆越低 | 0.48× | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资EULSH
| Q4 25 | $52.4M | $1.6M | ||
| Q3 25 | $91.9M | $4.5M | ||
| Q2 25 | $26.9M | $5.0M | ||
| Q1 25 | $29.7M | $1.5M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $2.7M |
总债务EULSH
| Q4 25 | $110.0M | $2.4M | ||
| Q3 25 | $109.3M | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K |
股东权益EULSH
| Q4 25 | $229.2M | $12.2M | ||
| Q3 25 | $248.6M | $7.0M | ||
| Q2 25 | $264.7M | $2.8M | ||
| Q1 25 | $267.9M | $749.8K | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $3.6M |
总资产EULSH
| Q4 25 | $430.4M | $24.3M | ||
| Q3 25 | $441.9M | $18.6M | ||
| Q2 25 | $359.4M | $14.4M | ||
| Q1 25 | $362.6M | $9.9M | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | — | $10.8M |
负债/权益比EULSH
| Q4 25 | 0.48× | 0.20× | ||
| Q3 25 | 0.44× | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.9M | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | $7.2M | — |
| 自由现金流率自由现金流/营收 | 57.8% | — |
| 资本支出强度资本支出/营收 | 46.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-45.0M | — |
8季度趋势，按日历期对齐
经营现金流EULSH
| Q4 25 | $12.9M | $-453.5K | ||
| Q3 25 | $-20.3M | $-4.0M | ||
| Q2 25 | $-9.9M | $-483.7K | ||
| Q1 25 | $-7.7M | $-238.3K | ||
| Q4 24 | — | $-530.2K | ||
| Q3 24 | — | $-1.4M |
自由现金流EULSH
| Q4 25 | $7.2M | — | ||
| Q3 25 | $-26.3M | — | ||
| Q2 25 | $-14.1M | $-497.4K | ||
| Q1 25 | $-11.7M | — | ||
| Q4 24 | — | $-560.5K | ||
| Q3 24 | — | $-1.4M |
自由现金流率EULSH
| Q4 25 | 57.8% | — | ||
| Q3 25 | -296.6% | — | ||
| Q2 25 | -385.2% | -7.9% | ||
| Q1 25 | -64.1% | — | ||
| Q4 24 | — | -15.6% | ||
| Q3 24 | — | -34.5% |
资本支出强度EULSH
| Q4 25 | 46.7% | — | ||
| Q3 25 | 68.0% | — | ||
| Q2 25 | 115.1% | 0.2% | ||
| Q1 25 | 21.7% | 0.0% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EU
暂无分部数据
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
